Theseus Pharmaceuticals
United States
45 articles about Theseus Pharmaceuticals
-
Theseus Pharmaceuticals to Participate Virtually in Wedbush PacGrow Healthcare Conference
8/3/2022
Theseus Pharmaceuticals, Inc. today announced that it will participate virtually in the 2022 Wedbush PacGrow Healthcare Conference, taking place August 9-10, 2022.
-
Life sciences organizations and companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences - May 19, 2022
5/19/2022
Theseus Pharmaceuticals, Inc. announced that the company will participate virtually in the H.C. Wainwright Global Investment Conference taking place May 23-26, 2022 and in-person in the Jefferies Healthcare Conference taking place June 8-10, 2022.
-
Theseus Pharmaceuticals Appoints Don Hayden to Board of Directors
5/18/2022
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced the appointment of Don Hayden to its Board of Directors.
-
Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2022 Financial Results
5/12/2022
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced business highlights and reported financial results for the first quarter ended March 31, 2022.
-
Theseus Pharmaceuticals Announces Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual Meeting
4/8/2022
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), today announced preclinical data characterizing next-generation pan-variant EGFR inhibitors that will be detailed in a live poster presentation at the American Association for Cancer Research (AACR) 2022 Annual Meeting.
-
Theseus Pharmaceuticals to Participate Virtually in Needham Healthcare Conference
4/5/2022
Theseus Pharmaceuticals, Inc. announced that it will participate in the 21st Annual Needham Virtual Healthcare Conference, taking place April 11-14, 2022.
-
Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results
3/10/2022
Theseus Pharmaceuticals, Inc. announced business highlights and reported financial results for the fourth quarter and full year ended December 31, 2021.
-
Theseus Pharmaceuticals to Present Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual Meeting
3/8/2022
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), today announced that the Company will present a poster highlighting the characterization of potent and selective next-generation EGFR inhibitors at the American Association for Cancer Research (AACR) 2022 Annual Meeting.
-
Theseus Pharmaceuticals to Participate Virtually in SVB Leerink Global Healthcare Conference
2/9/2022
Theseus Pharmaceuticals, Inc. today announced that Tim Clackson, Ph.D., President and Chief Executive Officer of Theseus, will participate in a virtual fireside chat for the 11th Annual SVB Leerink Global Healthcare Conference, taking place February 14-18, 2022.
-
Theseus Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for THE-630 for the Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)
2/2/2022
Theseus Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the company's lead candidate THE-630, a small-molecule oral pan-variant KIT inhibitor, for the treatment of patients with advanced gastrointestinal stromal tumors (GIST).
-
Theseus Pharmaceuticals Announces First Patient Treated with THE-630 in Phase 1/2 Study in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)
1/10/2022
Theseus Pharmaceuticals, Inc. announced that the first patient has been treated in the Phase 1 portion of Theseus' ongoing Phase 1/2 study to evaluate lead candidate, THE-630, in patients with advanced gastrointestinal stromal tumors.
-
Omega raised $650 million, which it plans to invest in life science companies in the U.S. and Europe.
-
Theseus Pharmaceuticals Appoints Alicja Januszewicz as Senior Vice President, People and Culture
12/16/2021
Theseus Pharmaceuticals, Inc. today announced the appointment of Alicja Januszewicz , Ph.D. as Senior Vice President, People and Culture.
-
Theseus Pharmaceuticals Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results
11/15/2021
Theseus Pharmaceuticals, Inc., a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, announced business and program highlights and reported financial results for the third quarter ended September 30, 2021.
-
Theseus Pharmaceuticals to Participate Virtually in Jefferies London Healthcare Conference
11/10/2021
Theseus Pharmaceuticals, Inc. announced that Tim Clackson, Ph.D., President and Chief Executive Officer of Theseus, will participate in a virtual fireside chat for the 12th Annual Jefferies London Healthcare Conference, taking place November 16-19, 2021.
-
Theseus Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for THE-630, a Pan-Variant KIT Inhibitor in Development for the Treatment of Gastrointestinal Stromal Tumors (GIST)
11/1/2021
Theseus Pharmaceuticals, Inc. today announced U.S. Food and Drug Administration (FDA) clearance of an investigational new drug (IND) application to evaluate THE-630
-
Theseus Pharmaceuticals Announces Pricing of Initial Public Offering - Oct 07, 2021
10/7/2021
Theseus Pharmaceuticals, Inc., a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, announced the pricing of its initial public offering of 10,000,200 shares of its common stock at a price to the public of $16.00 per share.
-
Theseus Pharmaceuticals Appoints Kathy Yi to Board of Directors and Chair of Audit Committee
6/10/2021
Theseus Pharmaceuticals, a biotechnology company shaping the future of targeted oncology by developing best-in-class, pan-variant kinase inhibitors, announced the appointment of Kathy Yi, Chief Financial Officer of Cerevel Therapeutics, to its Board of Directors, where she will serve as Chair of the Audit Committee.
-
Theseus Pharmaceuticals Appoints Brad Dahms as Chief Financial Officer
6/2/2021
Theseus Pharmaceuticals, a biotechnology company shaping the future of targeted oncology by developing best-in-class, pan-variant kinase inhibitors, announced the appointment of Brad Dahms as Chief Financial Officer.